Recent research funded by the National Institutes of Health (NIH) indicates that an experimental drug derived from common antivirals may help reverse vision loss and motor impairment in animal models of multiple sclerosis (MS).
Key Takeaways
- An experimental compound named kamuvudine-9 (K-9) helped mice recover from existing paralysis and vision loss linked to an MS-like state.
- Research suggests K-9 operates by blocking the inflammasome, an internal mechanism in the brain and spinal cord that triggers cell death.
- An analysis of over 3 million patient records revealed that individuals taking related antiviral medications experienced lower rates of MS and fewer relapses.
- K-9 was modified by University of Virginia researchers to eliminate antiviral traits that cause long-term side effects while retaining its protective qualities.
What the Source Says
According to findings highlighted by the NIH and the National Eye Institute (NEI), traditional MS therapies focus on restraining adaptive immune cells to prevent future relapses. However, standard therapies generally do not repair pre-existing nerve damage and often suppress broad immunity.
In mouse models, University of Virginia scientists observed that K-9 shut down two distinct pathways of inflammasome activation. This action shielded nerve fibers and their insulating myelin sheaths from degeneration, while also lowering blood levels of neurofilament light chain, a key marker of nerve damage. Animals receiving K-9 demonstrated significant recovery in both sight and movement, outperforming those given standard MS medication.
Additionally, researchers inspected insurance claims across three U.S. patient populations. Individuals taking antiviral drugs called NRTIs showed lower rates of MS diagnoses and fewer relapses. While K-9 has already been tested in clinical trials for conditions like diabetic macular edema and thyroid eye disease, scientists hope to advance K-9 into clinical trials for MS and ALS in the near future.
Practical Notes
It is important to remember that these findings are primarily based on laboratory animal models and observational records. Specific human trial start dates, treatment duration, and potential human dosages were not specified in the source; please check the official notice.
Always talk to your doctor before making decisions about your health, medical conditions, or medications.
Source: NIH News Releases · Published September 26, 2026
This article is for general information only and is not medical advice. Talk to your doctor before making health decisions.